

Themed Section: Cannabinoids 2013

COMMENTARY

High hopes for CB₂ receptors in neurogenesis

Eric J Downer

Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland

Correspondence

Dr Eric J Downer, Department of Anatomy and Neuroscience, University College Cork, Western Gateway Building, Cork, Ireland.
E-mail: edowner@ucc.ie

Keywords

cannabinoid; CB₂ cannabinoid receptor; neural stem cells; neurogenesis; HIV-1

Received

3 December 2013

Accepted

3 December 2013

During life, new neurons are continually added to hippocampal circuitry, with evidence suggesting that these adult-born neurons are functionally linked to cognition and emotion. The mammalian brain contains actively dividing neural stem cells in discrete regions, including the subventricular zone of the lateral ventricles and the subgranular zone of the dentate gyrus. Once mature, these neurons integrate into neuronal networks, forming synaptic connections with interneurons, mossy cells and CA3 pyramidal cells

LINKED ARTICLE

This article is a commentary on Avraham *et al.*, pp. 468–479 of volume 171 issue 2. To view this paper visit <http://dx.doi.org/10.1111/bph.12478>

Abbreviations

NPCs, neural progenitor cells; NSCs, neural stem cells; SGZ, subgranular zone; SVZ, subventricular zone; Tg, transgenic

The fate of neural stem cells (NSCs) in the adult brain is influenced by a variety of signalling molecules present in their microenvironment, including neurotransmitters (Song *et al.*, 2012), growth factors (Fournier *et al.*, 2012), cytokines (Vallieres *et al.*, 2002) and elements of the endocannabinoid system (Galve-Roperh *et al.*, 2013). Cannabinoids include the products of the cannabis plant (*Cannabis sativa* L.), the endogenous cannabinoids (endocannabinoids) and the synthetic cannabinoid ligands. Cannabinoids elicit a wide range of effects via two classes of G protein-coupled cannabinoid receptors, CB₁ and CB₂ (receptor nomenclature follows Alexander *et al.*, 2013), the expression of which has been localized on glia, immune cells and neurons (Howlett *et al.*, 2002). CB₁ receptors are expressed at high levels throughout the brain, whereas expression of CB₂ receptors is restricted to glia, with some evidence of functional CB₂ receptors in neurons (Van Sickle *et al.*, 2005; Onaivi *et al.*, 2008; Xi *et al.*, 2011). The endocannabinoid system is linked with all aspects of human physiology and has an emerging neuromodulatory role in adult neurogenesis.

In a recent issue of the *British Journal of Pharmacology*, Avraham *et al.* (2014) examined the link between the endocannabinoid system and neurogenesis, using a model of HIV-associated dementia. The authors used GFAP/Gp120

transgenic (Tg) mice, a model that mimics the cognitive deficits observed in HIV-1 patients, with associated neuronal degeneration and deficits in hippocampal neurogenesis. They presented comprehensive evidence that treatment (for 20 days) of GFAP/Gp120 Tg mice with the CB₂ receptor-specific agonist, AM1241 (greater than 100-fold selectivity for CB₂ over CB₁), prevented deficits in neurogenesis in the hippocampal subgranular zone. They also presented a significant body of *in vitro* data demonstrating that AM1241 promoted the proliferation and differentiation of human NSCs, and furthermore prevented DNA fragmentation induced by administration of the HIV-1 glycoprotein Gp120.

Taken together, the results in this article demonstrated the neuroprotective role of CB₂ receptors against impaired neurogenesis, with relevance to the cognitive deficits seen in HIV-1 patients. The findings are consistent with earlier studies, indicating that NSCs and neural progenitor cells (NPCs) in the adult brain express both CB₁ and CB₂ receptors (Jiang *et al.*, 2005; Molina-Holgado *et al.*, 2007), and that CB₂ receptor agonists enhance proliferation of embryonic NSCs (Molina-Holgado *et al.*, 2007) and hippocampal NPCs (Palazuelos *et al.*, 2012). Indeed, studies in CB₂ receptor knockout mice have confirmed the role of this receptor in hippocampal proliferation (Palazuelos *et al.*, 2006). The

findings of Avraham *et al.* (2014) are novel. What remains unclear however are the intracellular signalling mechanisms governing these CB₂ receptor-mediated effects. AM1241 blunted astrogliosis in GFAP/Gp120 Tg mice, representing the strong possibility that one neuroprotective mechanism by which AM1241 could modulates neurogenesis was blocking inflammatory pathways. Indeed, neuroinflammation impairs neurogenesis (Monje *et al.*, 2003), and evidence from Marchalant *et al.* (2009) (cited by the authors) has strongly linked cannabinoid receptor activation with decreased neuroinflammation and the restoration of hippocampal neurogenesis in aged rats. This certainly represents a worthwhile avenue for further investigation in the GFAP/Gp120 Tg model.

The link between cannabinoids and HIV-1 viral infection is a relatively uncharted area of research, and the article by Avraham *et al.* (2014) also provides advances in this area. The results described in this article supplement previous evidence that cannabinoids inhibit HIV-1/Gp120-induced neuronal damage (Kim *et al.*, 2011; Hu *et al.*, 2013) and that HIV-1/Gp120 enhances endocannabinoid degradation (Maccarrone *et al.*, 2004). Neurological impairment afflicts a large proportion of HIV-1 patients, and the findings of Avraham *et al.* (2014) point to the existence of a strong link between the endocannabinoid system and neurogenesis, with relevance to HIV-associated neuropathology. Taken together, this article further strengthens the rationale for the development of CB₂ receptor-specific agonists as a class of therapeutics, acting as promising candidates to target NPC proliferation and neurogenesis, bypassing the undesired psychoactive effects of neuronal CB₁ receptor stimulation.

Conflict of interests

None.

References

- Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M *et al.* (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. *Br J Pharmacol* 170: 1459–1581.
- Avraham HK, Jiang S, Fu Y, Rockenstein E, Makriyannis A, Zvonok A *et al.* (2014). The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis. *Br J Pharmacol* 171: 468–479.
- Fournier NM, Lee B, Banasr M, Elsayed M, Duman RS (2012). Vascular endothelial growth factor regulates adult hippocampal cell proliferation through MEK/ERK- and PI3K/Akt-dependent signaling. *Neuropharmacology* 63: 642–652.
- Galve-Roperh I, Chiurchiu V, Diaz-Alonso J, Bari M, Guzman M, Maccarrone M (2013). Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. *Prog Lipid Res* 52: 633–650.
- Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA *et al.* (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol Rev* 54: 161–202.
- Hu S, Sheng WS, Rock RB (2013). CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. *PLoS ONE* 8: e77577.
- Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G *et al.* (2005). Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. *J Clin Invest* 115: 3104–3116.
- Kim HJ, Shin AH, Thayer SA (2011). Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp120-induced synapse loss. *Mol Pharmacol* 80: 357–366.
- Maccarrone M, Piccirilli S, Battista N, Del Duca C, Nappi G, Corasaniti MT *et al.* (2004). Enhanced anandamide degradation is associated with neuronal apoptosis induced by the HIV-1 coat glycoprotein gp120 in the rat neocortex. *J Neurochem* 89: 1293–1300.
- Marchalant Y, Brothers HM, Wenk GL (2009). Cannabinoid agonist WIN-55,212-2 partially restores neurogenesis in the aged rat brain. *Mol Psychiatry* 14: 1068–1069.
- Molina-Holgado F, Rubio-Araiz A, Garcia-Ovejero D, Williams RJ, Moore JD, Arevalo-Martin A *et al.* (2007). CB2 cannabinoid receptors promote mouse neural stem cell proliferation. *Eur J Neurosci* 25: 629–634.
- Monje ML, Toda H, Palmer TD (2003). Inflammatory blockade restores adult hippocampal neurogenesis. *Science* 302: 1760–1765.
- Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L *et al.* (2008). Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. *Ann N Y Acad Sci* 1139: 434–449.
- Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzman M, Galve-Roperh I (2006). Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. *FASEB J* 20: 2405–2407.
- Palazuelos J, Ortega Z, Diaz-Alonso J, Guzman M, Galve-Roperh I (2012). CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling. *J Biol Chem* 287: 1198–1209.
- Song J, Zhong C, Bonaguidi MA, Sun GJ, Hsu D, Gu Y *et al.* (2012). Neuronal circuitry mechanism regulating adult quiescent neural stem-cell fate decision. *Nature* 489: 150–154.
- Vallieres L, Campbell IL, Gage FH, Sawchenko PE (2002). Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. *J Neurosci* 22: 486–492.
- Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K *et al.* (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. *Science* 310: 329–332.
- Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR *et al.* (2011). Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. *Nat Neurosci* 14: 1160–1166.